Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval

Hollis Viray, David F McDermott, David J Einstein

Open source

DOI: 10.1080/14737140.2022.2088515
Published: 2022-06-17
Container: Expert Review of Anticancer Therapy
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14737140.2022.2088515,
  title = {Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval},
  author = {Hollis Viray and David F McDermott and David J Einstein},
  year = {2022},
  journal = {Expert Review of Anticancer Therapy},
  doi = {10.1080/14737140.2022.2088515},
  url = {https://doi.org/10.1080/14737140.2022.2088515}
}

RIS

TY  - JOUR
TI  - Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval
AU  - Hollis Viray
AU  - David F McDermott
AU  - David J Einstein
PY  - 2022
JO  - Expert Review of Anticancer Therapy
DO  - 10.1080/14737140.2022.2088515
UR  - https://doi.org/10.1080/14737140.2022.2088515
ER  -

APA

Viray, H., McDermott, D. F., & Einstein, D. J. (2022). Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2022.2088515

Source records

crossref · retrieved 2026-09-26T17:14:11.335Z